Abstract
Urethral bulking agents are used in the treatment of female stress urinary incontinence in a wide variety of patients. Numerous materials have been approved for use in the USA, each with inherent properties that can affect its efficacy and safety profile, but none with characteristics deemed ideal to be used as an injectable implant. Few comparative studies are available to clearly define superiority of one agent over another. Nevertheless, bulking agents have demonstrated efficacy in appropriately selected and informed patients and do represent a viable option for women who do not want more invasive therapy and who understand efficacy and duration are inferior to other surgical options.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance
Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61:37–49.
Luber KM. The definition, prevalence, and risk factors for stress urinary incontinence. Rev Urol. 2004;6:S3.
Hampel C, Wienhold D, Benken N, et al. Definition of overactive bladder and epidemiology of urinary incontinence. Urology. 1997;50:4.
Osborn DJ, Strain M, Gomelsky A, Rothschild J, Dmochowski R. Obesity and female stress urinary incontinence. Urology. 2013;82:759–63.
Dmochowski RR, Blaivas JG, Gormley A, et al. Update of AUA guideline on the surgical management of female stress urinary incontinence. J Urol. 2010;183:1906–14. A good summary of efficacy and adverse events of the surgical modalities for the treatment of female SUI based on a meta-analysis of the available literature.
Murless BC. The injection treatment of stress incontinence. J Obstet Gynecol Br Emp. 1938;45:521–4.
Anger JT, Weinberg AE, Albo ME, et al. Trends in surgical management of stress urinary incontinence among female Medicare beneficiaries. Urology. 2009;74:283–87.
Zoorob D, Karram M. Bulking agents: a urogynecology perspective. Urol Clin N Am. 2012;39:273–7.
Reynolds WS, Dmochowski RR. Urethral bulking: a urology perspective. Urol Clin N Am. 2012;39(3):279–87. A easy to read article on urethral bulking therapy, including historical and currently available agents.
Beisang AA, Ersek RA. Mammalian response to subdermal implantation of textured microimplants. Aesthet Plast Surg. 1992;16:83.
Lucas MG, Bedretdinova D, Bosch JLHR, et al. Guidelines on urinary incontinence. © European Association of Urology (EAU). Urinary Incontinence-Update March 2013.
Appell RA, McGuire EJ, DeRidder PA, et al. Summary of effectiveness and safety in the prospective, open, multicenter investigation of Contigen implant for incontinence due to intrinsic sphincteric deficiency in females. J Urol. 1994;151:418A.
Striker P, Haylen B. Injectable collagen for type 3 female stress incontinence: the first 50 Australian patients. Med J Aust. 1993;158:89–91.
Swami SK, Eckford SD, Abrams P. Collagen injections for female stress incontinence: conclusions of a multistage analysis and results. J Urol. 1994;151:479A.
DeLustro F, Keefe J, Fong AT, et al. The biochemistry, biology, and immunology of injectable collagens: Contigen Bard collagen implant in treatment of urinary incontinence. Pediatr Surg Int. 1991;6:245–51.
McPherson JM, Sawamura S, Armstrong R. An examination of the biologic response to injectable glutaraldehyde cross-linked collagen implants. J Biomed Mater Res. 1986;20:93–7.
Beavan A: Material properties and applications of Pyrolite® carbon. Materials Engineering 1990.
Appell RA. Collagen injection therapy for urinary incontinence. Urol Clin N Am. 1994;21:177–82.
Madjar S, Covington-Nichols C, Secrest CL. New periurethral bulking agent for stress urinary incontinence: modified technique and early results. J Urol. 2003;170:2327–9.
Lightner D, Calvosa C, Andersen R, et al. A new injectable bulking agent for treatment of stress urinary incontinence: results of a multicenter, randomized, controlled, double-blind study of Durasphere. Urology. 2001;58:12–5.
Chrouser KL, Fick F, Goel A, et al. Carbon coated zirconium beads in beta–glucan gel and bovine glutaraldehyde cross-linked collagen injections for intrinsic sphincteric deficiency: continence and satisfaction after extended follow-up. J Urol. 2004;171:1152–5.
23 Hurtado EA, Appell, RA. Surgery for stress urinary incontinence: minimally invasive procedures. In Badlani GH, Davila GW, Michel MC, de la Rosette J Continence. Springer London 2009, pp 149–164.
Berger MB, Morgan DM. Delayed presentation of pseudoabscess secondary to injection of pyrolytic carbon-coated beads bulking agent. Female Pelvic Med Reconstr Surg. 2012;18(5):303–5.
Ghoniem GM, Khater U. Urethral prolapse after durasphere injection. Int Urogynecol J Pelvic Floor Dysfunct. 2006;17(3):297–8.
Starkman JS, Scarpero H, Dmochowski RR. Emerging periurethral bulking agents for female stress urinary incontinence: is new necessarily better? Curr Urol Rep. 2006;7(5):405–13.
Belafsky PC, Postma GN. Vocal fold augmentation with calcium hydroxylapatite. Otolaryngol Head Neck Surg. 2004;131(4):351–4.
Dmochowski RR, Appell RA. Injectable agents in the treatment of stress urinary incontinence in women: where are we now? Urology. 2000;45(6 Suppl 1):32–40.
Mayer R, Dmochowski R, Appell RA, et al. Multicenter prospective randomized 52-week trial of calcium hydroxylapatite versus bovine dermal collagen for treatment of stress urinary incontinence. Urology. 2007;69:876–80.
Lai HH, Hurtado EA, Appell RA. Large urethral prolapse formation after calcium hydroxylapatite (Coaptite) injection. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19:1315–17.
Palma PC, Riccetto CL, Martins MH, et al. Massive prolapse of the urethral mucosa following periurethral injection of calcium hydroxylapatite for stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct. 2006;17:670–1.
Ghoniem G, Corcos J, Comiter C, et al. Durability of urethral bulking agent injection for female stress urinary incontinence: 2 yr mulitcenter study results. J Urol. 2010;183:1444–9.
Ghoniem G, Miller CJ. A systemic review and meta-analysis of Macroplastique for treating female stress urinary incontinence. Int Urogynecol J. 2013;24:27–36.
Ter Meulen PH, Berghmans LC, van Kerrebroeck PE. Systematic review: efficacy of silicone microimplants (Macroplastique) therapy for stress urinary incontinence in adult women. Eur Urol. 2003;44:573–82.
Herschorn S. Injection therapy for urinary incontinence. In Wein A, Kavoussi LR, Novick AC (10th edition) Campbell-Walsh urology. Philadelphia: Saunders Elsevier 2012, pp2168-85. This chapter from the definitive textbook of Urology provides an in depth background and review of bulking therapy for female SUI.
Madjar S, Sharma AK, Waltzer WC, et al. Periurethral mass formation following bulking agent injection for the treatment of urinary incontinence. J Urol. 2001;166(4):1350–3.
Henly DR, Barrett DM, Weiland TL, et al. Particulate silicone for use in periurethral injections: local tissue effects and search for migration. J Urol. 1995;153:2039–43.
Christensen LH, Nielsen JB, Mouritsen L, et al. Tissue integration of polyacryamide hydrogel: an experimental study of periurethral, perivesical, and mammary gland tissue in the pig. Dermatol Surg, Suppl. 2008;34:S68.
Bano F, Barrington JW, Dyer R. Comparison between porcine dermal implant (Permacol) and silicone injection (macroplastique) for urodynamic stress incontinence. Int Urogynecol J. 2005;16:147–50.
Sokol ER, Karram MM, Dmochowski R. Efficacy and safety of polyacrylamide hydrogel for the treatment of female stress incontinence: a randomized, prospective, mulitcenter North American Study. J Urol. 2014;192:843–9. A large RCT on the newest available bulking agent and whose study criteria included nearly one third of patients who were still symptomatic after other incontinence procedures.
Yokoyama T, Yoshimura N, Dhir R, et al. Persistence and survival of autologous muscle derived cells versus bovine collagen as potential treatment of stress urinary incontinence. J Urol. 2001;165:271–6.
Chermansky JC, Cannon TW, Torimoto K, et al. A model of instrinsic sphincteric deficiency in the rat: electrocauterization. Neurourol Urodyn. 2004;23:166–71.
Cannon TW, Lee JY, Somogyi G, et al. Improved sphincter contractility after allogenic muscle-derived progenitor cell injection into denervated rat urethra. Urology. 2003;62:958–63.
Peters KM, Dmochowski RR, Carr LK, et al. Autologous muscle derived cells for treatment of stress urinary incontinence in women. J Urol. 2014;192:469–76. This paper describes a novel therapy whose mechanism of action differs from traditional bulking agents and which has the potential to change the landscape of urethral bulking therapy.
Compliance with Ethics Guidelines
Conflict of Interest
Stephen Mock and W. Stuart Reynolds declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is part of the Topical Collection on Stress Incontinence and Prolapse
Rights and permissions
About this article
Cite this article
Mock, S., Reynolds, W.S. Bulking Agents for Stress Incontinence: Are They a Real Option?. Curr Bladder Dysfunct Rep 10, 46–51 (2015). https://doi.org/10.1007/s11884-014-0277-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11884-014-0277-0